EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic
EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic
Orgenesis Inc (NASDAQ:ORGS) has entered into a definitive agreement with MM OS Holdings, an affiliate of Metalmark Capital Partners, to acquire its approximate 25% stake in Octomera.
Orgenesis Inc（纳斯达克股票代码：ORGS）已与Metalmark Capital Partners的子公司MM OS Holdings签订了最终协议，收购其在Octomera约25％的股份。
Octomera is Orgenesis's cell processing services subsidiary, and the transaction allows the company to have 100% ownership of this business unit.
Octomera是Orgenesis的细胞处理服务子公司，该交易允许该公司拥有该业务部门的100％所有权。
In exchange, Metalmark will receive a royalty of 5% of the net revenue of Octomera's cell processing services for the three calendar years 2025-2027, along with a portion of the proceeds attributable to Octomera's cell processing services should there be a change of control in the next ten years.
作为交换，Metalmark将获得2025-2027三个日历年Octomera电池处理服务净收入的5％的特许权使用费，如果未来十年控制权发生变化，还将部分收益归因于Octomera的电池处理服务。
"Moreover, we believe that further support is coming from FDA and EMEA regulators that are taking initiatives to progress the guidelines for decentralized production, understanding that cost pressures, capacity constraints, and surging patient demand are encouraging hospitals to consider the paradigm-shifting decentralized approach that brings processing services closer to the patient and unlocking the associated benefits," said Vered Caplan, CEO of Orgenesis.
Orgenesis首席执行官韦德·卡普兰表示：“此外，我们认为，美国食品药品管理局和欧洲、中东和非洲监管机构将提供进一步的支持，这些监管机构正在采取举措推进分散生产指导方针，因为他们知道成本压力、产能限制和患者需求激增正在鼓励医院考虑转变范式的去中心化方法，使处理服务更接近患者并释放相关的好处。”
Price Action: ORGS shares closed at $0.32 on Tuesday.
价格走势：ORGS股价周二收于0.32美元。
译文内容由第三方软件翻译。